Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CS19
- Development stage
- Phase 1
- Lead developer
- Naval Medical Research Center
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
CS19 is a fimbrial colonization factor (CF) expressed by Enterotoxigenic *Escherichia coli* (ETEC), a major bacterial pathogen causing diarrheal illness, particularly in children in developing countries and travelers. This protein mediates the adhesion of ETEC to the host's intestinal epithelial cells, a critical step for establishing infection and subsequent toxin production. CS19 is recognized as a virulence factor and is being investigated as a potential antigen for the development of ETEC vaccines. CS19-expressing ETEC strains are also utilized in human and animal challenge models to study disease pathogenesis and evaluate vaccine candidates.
- Other names
- Colonization Factor 19
02
Targets
CS19 (Colonization surface antigen 19)
Beyond the preview
Go deeper on CS19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CS19.